Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134689 | 0.78 | ALDH1A1 (0.50) | EPHX2ALDH1A1NPSR1MEN1MAPK1 | |
| SCHEMBL21245251 | 0.78 | EPHX2 (0.50) | HSD17B10EPHX2ALDH1A1TSHRNPSR1 | |
| SCHEMBL2300337 | 0.78 | EPHX2 (0.53) | EPHX2MEN1MAPK1KMT2ADPP4 | |
| SCHEMBL27617726 | 0.75 | EPHX2 (0.51) | EPHX2ALDH1A1NPSR1MEN1MAPK1 | |
| SCHEMBL4369566 | 0.74 | ALDH1A1 (0.58) | HSD17B10EPHX2ALDH1A1TSHRNPSR1 | |
| Acetic Acid SCHEMBL703302 | 0.74 | ALDH1A1 (0.46) | EPHX2ALDH1A1NPSR1MEN1MAPK1 | |
| Hydrochloric Acid SCHEMBL1677927 | 0.74 | EPHX2 (0.50) | EPHX2ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL29032062 | 0.73 | EPHX2 (0.56) | EPHX2ALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL783009 | 0.73 | CA2 (0.41) | MEN1KMT2A | |
| SCHEMBL133579 | 0.72 | ALDH1A1 (0.54) | HSD17B10EPHX2ALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | HSD17B10 524/4885EPHX2 1889/4885ALDH1A1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.